Back to search

Switzerland· 66934001

Oncaspar 750 UI/ml, poudre pour solution injectable

A pegaspargase product containing pegaspargasum, registered in Switzerland by Servier (Suisse) SA and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01XX24

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedOncaspar 750 UI/ml, poudre pour solut…ATCL01XX24REGISTER NO.66934001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Pegaspargase is registered in 15 of 19 countries.

Countries holding a registration under ATC L01XX24 (pegaspargase), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 9 of them publish a price we can compare per daily dose

Pegaspargase · ATC L01XX24

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
pegaspargasum
Manufacturer
Servier (Suisse) SA
Country
Switzerland (CH)
ATC code
L01XX24
ATC class
Pegaspargase
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680669340018
    Durchstf 1 Stk
    CHF 1765.3

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

441 interactions on record for pegaspargase.

Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Pegaspargase · interactions on record

441 records

  • 30 severe
  • 411 moderate

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • ClotrimazoleA01AB18moderate
  • Chenodeoxycholic acidA05AA01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c19d1bde-806f-4046-b10a-45ac2fdea5ab
GET /v1/drugs/c19d1bde-806f-4046-b10a-45ac2fdea5ab?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "pegaspargasum 3750 UI",
  "valid_from": "2019-10-01",
  "limitations": "[{\"description\":\"Oncaspar ist als Bestandteil einer antineoplastischen Kombinationstherapie bei akuter lymphatischer Leukämie (ALL) angezeigt.<br>\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2019-10-01\"}]",
  "galenic_form": "Trockensub 3750 IE",
  "therapeutic_area": null,
  "sl_inclusion_date": "2019-10-01",
  "self_retention_pct": 10
}

See everything about pegaspargase.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.